| Name | Title | Contact Details |
|---|---|---|
Clay Britton |
Vice President of Legal and Compliance Services and General Counsel | Profile |
Dan Roehler |
Chief Compliance Officer | Profile |
Matt All |
President and Chief Executive officer | Profile |
Scott Raymond |
Vice President of Legal Services and General Counsel | Profile |
We are one of the nation`s first health departments and trace our roots back to 1799, when Paul Revere was named Boston`s first health officer. Back then, the board of health was formed to fight a potential outbreak of cholera. Taking innovative strides to save lives, health officials posted signs on lampposts, held meetings and led an early-day public information campaign to reduce deaths due to cholera, a highly preventable disease. Two hundred years later, that tradition of prevention continues through the Boston Public Health Commission. While we are the country`s oldest health department, we pride ourselves on having some of the most innovative services for our residents. Described as "the most activist arm of city government," by the Boston Globe, the Commission has a vigorous commitment to the health of Boston.
Norwalk Hospital is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Norwalk, CT. To find more information about Norwalk Hospital, please visit www.norwalkhealth.org
Johnson Regional Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Clarksville, AR. To find more information about Johnson Regional Medical Center, please visit www.jrmc.com
Toby Orthopaedics is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.